Search results
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 9 hours agoModerna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 9 hours agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 5 hours ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 2 hours agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.
Moderna Focused on Cutting Costs, RSV Vaccine
Bloomberg· 5 hours agoModerna Chief Executive Officer Stéphane Bancel talks about how the biotech giant is cutting costs and developing new vaccines. The drugmaker expects to...
Moderna Beats Quarterly Estimates as Cost-Cutting Pares Losses
Bloomberg· 9 hours agoModerna Inc. reported a narrower first-quarter loss than Wall Street had expected, as the biotech...
Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch | Invezz
Invezz· 9 hours agoModerna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year,...
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga· 42 minutes agoMerck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockbuster ...
Moderna makes several cost-cutting moves, leans into AI - Boston Business Journal
The Business Journals· 6 hours agoAs Moderna Inc. works toward expanding its approved products beyond its Covid-19 vaccine, the...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 5 hours agoMuch of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a...
